CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

vistusertib

Small moleculeexperimental

Clinical trial activity

34 trials · 30 clinical orgs · 0 marketing orgs

Phase 1
17
Phase 2
25
Phase 3
0
Phase 4
0

Earliest trial started Dec 1, 2009 (NCT01026402)

Timeline

2000s

  1. Jan 1, 2009

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2013

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CNC(=O)c1cccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)c1
Mol. weight
462.55 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • azd2014
  • azd2014
  • azd 2014
  • azd 2014
  • azd-2014
  • azd-2014
  • vistusertib
  • vistusertib
  • vistusertib

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03334617Phase 2Dec 18, 2017AstraZeneca, University of Texas at Houston
NCT03366103Phase 1/Phase 2 (Phase 2)Nov 29, 2017Johns Hopkins University, National Cancer Institute (NCI)
NCT03205046Phase 1/Phase 2 (Phase 2)Jul 11, 2017Acerta Pharma
NCT03166176Phase 2Jul 1, 2017Sungkyunkwan University
NCT03166904Phase 2Jul 1, 2017Sungkyunkwan University
NCT03071874Phase 2Apr 15, 2017AstraZeneca, Harvard University, National Cancer Institute (NCI)
NCT03106155Phase 2Apr 1, 2017AstraZeneca, Sungkyunkwan University
NCT03082833Phase 2Feb 1, 2017Sungkyunkwan University
NCT03061708Phase 2Feb 1, 2017Sungkyunkwan University
NCT02546661Phase 1Oct 3, 2016AstraZeneca, SCRI Development Innovations, University of London
NCT02831257Phase 2Jul 1, 2016AstraZeneca, Department of Defense, Harvard University
NCT02813135Phase 1/Phase 2 (Phase 2)Jun 1, 2016Institut Gustave Roussy, National Cancer Institute, France
NCT02780830Phase 1Jun 1, 2016AstraZeneca, SCRI Development Innovations
NCT02730923Phase 1/Phase 2 (Phase 2)Apr 1, 2016Centre Leon Berard
NCT02640755Phase 1Jan 28, 2016AstraZeneca, IQVIA, The Christie NHS Foundation Trust
NCT02599714Phase 1/Phase 2 (Phase 2)Dec 7, 2015AstraZeneca, SCRI Development Innovations
NCT02619864Phase 1/Phase 2 (Phase 2)Nov 1, 2015AstraZeneca, Canadian Cancer Trials Group, University of Toronto
NCT02576444Phase 2Nov 1, 2015Harvard University, Vanderbilt University, Yale University
NCT02752204Phase 2Oct 1, 2015AstraZeneca, Bloodwise, Cancer Research UK, University of Birmingham, University of Oxford
NCT02583542Phase 1/Phase 2 (Phase 2)Jun 1, 2015AstraZeneca, Cancer Research UK, University of London
Showing 20 of 34 trials
Page 1 / 2

Organizations

Research & Development (30)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
AstraZenecaFor profit241022009
Sungkyunkwan UniversityAcademic/Hospital6612015
University of LondonAcademic/Hospital5322013
Cancer Research UKAcademic/Hospital4012013
SCRI Development InnovationsFor profit4022012
Harvard UniversityAcademic/Hospital3212015
Institut Gustave RoussyAcademic/Hospital3112014
National Cancer Institute (NCI)Government3112014
Fondation ARCAcademic/Hospital2012014
Royal Marsden Hospital NHS TrustAcademic/Hospital2112009
UNICANCERAcademic/Hospital2212014
University of BirminghamAcademic/Hospital2212015
University of Texas at HoustonAcademic/Hospital2112014
University of TorontoAcademic/Hospital2022013
Acerta PharmaFor profit1112017
BloodwiseAcademic/Hospital1012015
Canadian Cancer Trials GroupAcademic/Hospital1112015
Centre Leon BerardAcademic/Hospital1112016
Department of DefenseGovernment1012016
Groupe Hospitalier Paris Saint JosephAcademic/Hospital1012014
30 organizations
Page 1 / 2